Musakanya Chingandu

Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antiviral activity trial

Authors: Kamphuis AEM, Salvadori N, Mujuru HA, Bwakura-Dangarembizi M, Kisitu GP, Matovu F, Kaudha E, Mulindwa A, Jacobs TG, Than-in-at K, Cressey TR, Nardone A, Lallemant M, Colbers A, Burger DM Published in: The Lancet [button...

read more

Closing the paediatric HIV treatment gap

This article was written by Anne Kamphuis and Prof David Burger, Radboud University Medical Centre. It is taken from the Penta 2025 Annual Report. Despite significant advances in HIV treatment in recent years, these have mainly benefited adults. Children have...

read more

Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials

Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White...

read more

UNIVERSAL 1 trial enrols first patients

A significant milestone has been reached in the fight against paediatric HIV with the enrolment of the first participants in the UNIVERSAL 1 trial. This achievement is a testament to the tremendous effort and dedication of the site staff in Uganda and Zimbabwe. ...

read more